BiotechTube
AccuDava

AccuDava

San Diego, United States· Est.
accudava.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AccuDava is a private, pre-revenue diagnostics and therapeutic development company tackling a critical unmet need in oncology: platinum chemotherapy resistance. The company has developed a novel diagnostic method, initially validated in ovarian and lung cancers, designed to accurately identify non-responsive patients before treatment begins. Supported by multiple NIH SBIR grants and a strong IP portfolio, AccuDava aims to personalize cancer treatment decisions and is concurrently developing a glycan-based technology to circumvent resistance. Its leadership combines scientific expertise in glycobiology and oncology with business development acumen.

OncologyOvarian CancerLung Cancer

Technology Platform

Glycan-based platform for predicting and overcoming platinum chemotherapy resistance in cancer. Utilizes specific glycan signatures as biomarkers for diagnostic prediction and as targets for therapeutic intervention to increase drug uptake in resistant cells.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive unmet need in predicting and overcoming platinum chemotherapy resistance creates a large addressable market in major cancers like ovarian and lung.
An accurate predictive diagnostic could become a standard-of-care test, driving rapid adoption.
The dual diagnostic-therapeutic approach offers a unique, integrated solution that could command significant partnership or acquisition interest.

Risk Factors

High technical risk that the glycan biomarkers will not validate in broader clinical studies.
Heavy reliance on uncertain non-dilutive grant funding for continued operations.
Significant commercialization challenges include securing payer reimbursement for a new diagnostic and navigating complex FDA pathways for a novel therapeutic.

Competitive Landscape

The predictive oncology diagnostics space is competitive, with companies like Foundation Medicine (Roche) and Caris Life Sciences offering broad genomic profiling, though not specifically focused on glycan-based platinum resistance prediction. The therapeutic chemosensitizer field has seen limited success, representing both a challenge and an opportunity for AccuDava's novel approach. Its glycan-focused IP may provide a defensible niche.

More companies in Diagnostics & Precision Medicine →More companies in United States →